Research Projects & Grants

College/University

  • UCI - BMS CA 180-097: A phase II trial of dasatinib (Sprycel®) in subjects with hormone-refractory prostate cancer previously treated with chemotherapy, Role: PI, University of California, Irvine, (08/2010 - 08/2011) Status: Completed
  • Millennium 03-1218/34102-033 MUSC CTO #100822: VELCADE® (bortezomib) for injection therapy for early relapsed prostate cancer, Role: PI, Medical University of South Carolina, (09/2009 - 09/2010) Status: Completed
  • Phase II study of mobilization with intermediate or high dose filgrastim after ESHAP chemotherapy for intermediate and high grade lymphomas, Role: Investigator, Johns Hopkins University, Status: Completed

Federal

  • SWOG - PACCT-1: Program of the assessment of clinical tests (PACCT-1): Trial assigning individualized options for treatment: the TAILORx trial, Role: Investigator, Eastern Cooperative Oncology Group, (11/2024 - 11/2025) Status: Approved
  • Clinical study to evaluate the methylation signature of head and neck squamous cell carcinoma pain, Role: Other Significant Contributor, National Institutes of Health/DHHS, (08/2021 - 07/2026) Status: Awarded
  • CALGB-40502: A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound NAB-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer, Role: Investigator, National Cancer Institute/NIH/DHHS, (07/2016 - 07/2017) Status: Completed
  • LLU Center for Health Disparities Research, Role: Collaborator, National Institute of Minority Health and Health Disparities/NIH/NIMHD, (07/2012 - 01/2020) Status: Closed
  • CAM use among cancer patients at LLUMC, Role: Investigator, National Institutes of Health/DHHS, (02/2010 - 02/2011) Status: Completed
  • NASBP B-27.1 A trial to evaluate the worth of serum ErbB-2 extracellular domain and serum ErbB-2 antibodies in predicting response to preoperative chemotherapy and long-term outcome in patients with operable breast cancer who are participating in NSABP Protocol B-27, Role: PI, National Cancer Institute/NIH/DHHS, (07/2009 - 07/2010) Status: Completed
  • NSABP C-06. A clinical trial comparing oral Uracil/Ftorafur plus leucovorin with 5-fluorouraceil (5-FU) plus leucovorin in the treatment of patients stages II and III carcinoma of the colon, Role: Investigator, National Cancer Institute/NIH/DHHS, (08/2008 - 08/2009) Status: Completed
  • FHCRC - 1630.00 - a multi-center pilot study of high-dose immunoablative therapy using cyclophosphamide and anti-thymocyte globulin and followed by autologous or syngeneic peripheral blood stem cell transplantation for patients with refractory systemic lupus erythematosus, Role: Investigator, National Institutes of Health/DHHS, (05/2003 - 05/2004) Status: Completed

For Profit Organization

  • SWOG-S0820: A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer, phase III - preventing adenomas of the colon with eflornithine and sulindac (PACES), Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • SWOG-A011106:ALTernate approaches for clinical stage II or III estrogen receptor positive breast cancer NeoAdjuvant TreEatment (ALTERNATE) in postmenopausal women: a phase III study, Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • Amgen Inc., 20190135: A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (plNN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H), Role: Investigator, Amgen, Inc., (06/2024 - 06/2025) Status: Approved
  • Southwest Oncology Group (SWOG) Protocol N063D/BIG2-06-ALTTO - Adjuvant lapatinib and/or trastuzumab treatment optimisation study. A randomized, multi-center, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer, Role: Investigator, Southwest Oncology Group, (03/2025 - 03/2026) Status: Approved
  • SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer, Role: PI, Southwest Oncology Group, (04/2024 - 09/2024) Status: Completed
  • Amgen 20190135: A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (plNN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation, Role: Investigator, Amgen, Inc., (02/2025 - 02/2026) Status: Approved
  • SWOG E1697: Phase III randomized study of four weeks high dose IFN-a2b in stage T2bN0, T3a-bN0, and T1-4, N1a2a (microscopic) melanoma, Role: Investigator, Southwest Oncology Group, (02/2025 - 02/2026) Status: Approved
  • Amgen 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation Amgen 20190135-C: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol C), Role: Investigator, Amgen, Inc., (12/2024 - 12/2025) Status: Approved
  • SWOG-S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER-2 negative breast cancer with recurrence score (RS) of 25 or less. RxPONDER: A clinical trial Rx for positive node, endocrine responsive breast cancer, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
  • SWOG-S1207: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of EVEROLIMUS in patients with high-risk hormone receptor-positive AND HER2/neu negative breast cancer e3 breast cancer study - evaluating everolimus with endocrine therapy, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
  • ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, Atara Biotherapeutics, Inc., (12/2024 - 12/2025) Status: Approved
  • SWOG EA5142:adjuvant nivolumab in resected lung cancers (ANVIL) a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers, Role: Investigator, Southwest Oncology Group, (11/2024 - 11/2025) Status: Approved
  • SWOG-S1216: a phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer, Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • SWOG-S1216: a phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer, Role: PI, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • SWOG A151216: adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST), Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • Apollomics Inc. APL-101-01 (SPARTA): Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors, Role: Investigator, Apollomics Inc., (09/2024 - 09/2025) Status: Approved
  • SWOG S1507: A phase II trial of Trametinib with Docetaxel in patients with KRAS mutation positive non-small cell lung cancer (NSCLC) and progressive disease following one or two prior systematic therapies, Role: Investigator, Southwest Oncology Group, (05/2023 - 05/2024) Status: Completed
  • Merck Sharp & Dohme Corp., MK3475-361: Phase III randomized controlled trial of pembrolizumab with or without chemo vs chemo in advanced urothelial carcinoma, Role: PI, Merck, (01/2023 - 01/2024) Status: Completed
  • C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2), Role: PI, Pfizer Inc., U.S. Pharmaceuticals Group, (07/2021 - 07/2022) Status: Completed
  • Novartis CACZ885V2301: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2), Role: Investigator, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
  • SWOG A031201: Phase III trial of enzalutamide (NSC #766085) versus anzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer, Role: Investigator, Southwest Oncology Group, (04/2020 - 04/2021) Status: Completed
  • Bio-Cancer Treatment International Ltd.-BCT-100-005: Recombinant human arginase 1 (rhArg1) in patients with advanced, arginine auxotrophic solid tumors: Dose escalation, safety and PK/PD, Role: PI, Bio-Cancer Treatment International, Ltd., (04/2020 - 04/2021) Status: Completed
  • Novartis - CRAD001Y24135: an open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally advanced breast cancer, Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2020 - 02/2021) Status: Completed
  • CLDK378A2112: A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC), Role: Investigator, Novartis Pharmaceuticals Corporation, (01/2020 - 01/2021) Status: Completed
  • E5202 Phase III SWOG endorsed CTSU study: a randomized phase III study comparing 5-FU, leucovorin and oxaliplatin versus 5-FU, leucovorin, oxaliptatin and bevacizumab in patients with stage II colon cancer at high risk for recurrence to determine prospectively and prognostic value of molecular markers, Role: Investigator, Southwest Oncology Group, (01/2020 - 01/2021) Status: Completed
  • Southwest Oncology Group (SWOG) protocol #E2805: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma, Role: Investigator, Southwest Oncology Group, (09/2019 - 09/2020) Status: Completed
  • SWOG -EAY131: Molecular analysis for therapy choice (MATCH), Role: Investigator, Southwest Oncology Group, (08/2019 - 08/2020) Status: Completed
  • Bristol-Myers Squibb - CA204112: A phase 2, single arm study of safety of elotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone for newly diagnosed or relapsed/refractory multiple myeloma patients, Role: Investigator, Bristol-Myers Squibb Company, (07/2019 - 07/2020) Status: Completed
  • SWOG S1318: A phase II study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for patients >= 65 years of age with newly diagnosed Philadelphia-chromosome negative acute lymphoblastic leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for patients >= 65 years of age with newly diagnosed Philadelphia-chromosome positive (Ph+) ALL, Role: Investigator, Southwest Oncology Group, (08/2018 - 08/2019) Status: Completed
  • Southwest Oncology Group (SWOG) - S0800: A randomized phase II trial of weekly nanoparticle albumin bound pacilitaxel (nab-pacilitaxel) (NSC-736631) with or without bevacizumab, either preceded by or followed by Q 2 week doxorubicin (A) and cyclophosphamide (c) plus pegfilgrastim (PEG-G) as neoadjuvant therapy for inflammatory and locally advanced her-2/neu negative breast cancer, Role: Investigator, Southwest Oncology Group, (05/2018 - 05/2019) Status: Completed
  • Taiho Oncology Inc. TO-TAS-114-201: A randomized, open-label, multi-center, international phase 2 study of TAS-114 in combination with S-1 in patients with advanced or metastatic non-small cell lung cancer, Role: Investigator, Taiho Oncology Inc., (10/2017 - 10/2018) Status: Completed
  • Mirati Therapeutics,Inc., 265-109: Phase 2, parallel-arm study of MGCD265 in patients with locally advanced or metastatic non-small cell lung cancer with activating genetic alterations in mesenchymal-epithelial transition factor, Role: Investigator, Mirati Therapeutics, (10/2017 - 10/2018) Status: Completed
  • Astellas Pharma Global Development, Inc. 8273-CL-0302: An open-label, randomized phase 3 efficacy study of ASP8273 vs. erlotinib or gefitinib in first-line treatment of patients with stage IIIB/IV non-small cell lung cancer tumors with EGFR activating mutations (SOLAR study), Role: Investigator, Astellas Pharma US, Inc., (06/2017 - 06/2018) Status: Completed
  • SWOG 9512. A phase III study of adjuvant Ganglioside vaccination GM2-KLH/QS-21 therapy vx hihg-dose inferferon Alfa-2b (IntronA) for high risk melanoma (T4>4mm primary or regional lymph node metastasis, Role: Investigator, Southwest Oncology Group, (05/2017 - 05/2018) Status: Completed
  • Midostaurin (PKC412) Individual Patient Program (IPP) for an individual patient 18 years of age and older with newly-diagnosed FLT3-mutated AML and eligible for standard induction and consolidation chemotherapy, Role: Investigator, Novartis Pharmaceuticals Corporation, (01/2017 - 01/2018) Status: Completed
  • Eli Lilly & Co I3Y-MC-JPBK JUNIPER: A randomized phase 3 study of Abemaciclib plus best supportive care versus erlotinib plus best supportive care in patients with stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapy, Role: Investigator, Eli Lilly & Co., (11/2016 - 11/2017) Status: Completed
  • Millennium Pharmaceuticals, Inc. - C05013: An open-label, randomized, phase 2 study to assess the effectiveness of RCHOP with or without VELCADE® in previously untreated patients with non-germinal center B-Cell-like diffuse large B-cell lymphoma, Role: PI, Millennium Pharmaceuticals, Inc., (10/2015 - 10/2016) Status: Completed
  • SWOG 9250 - Phase III Intergroup Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection, Followed by 5-FU/Levamisole for Patients with Colon Cancer, Role: PI, Southwest Oncology Group, (06/2015 - 06/2016) Status: Completed
  • SWOG-9346 Intermittent androgen deprivation in patients with stage D2 Prostate Cancer, Phase III, Role: PI, Southwest Oncology Group, (03/2015 - 03/2016) Status: Completed
  • SWOG-S0500 - A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment, Role: Investigator, Southwest Oncology Group, (09/2014 - 09/2015) Status: Completed
  • SWOG N0147. A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer, Role: Investigator, Southwest Oncology Group, (05/2014 - 05/2015) Status: Completed
  • Sanofi-aventis - POP6792: Phase I safety and pharmacokinetic study of XRP6258 (cabazitaxel) in advanced solid tumor patients with varying degrees of hepatic impairment, Role: Investigator, Sanofi-Aventis U.S., Inc., (05/2014 - 05/2015) Status: Completed
  • Daiichi Sankyo Pharma Development - DS2248-A-U101 - A phase 1, open label, multiple-ascending dose study of DS-2248, an orally biovailable heat shock protein 90 inhibitor in subjects with advance solid tumors, Role: Investigator, Daiichi Sankyo Pharma Development, (05/2014 - 05/2015) Status: Completed
  • Genentech - U2963n: The national lymphocare study: an observational study of treatment, outcomes, and prognosis in patients with follicular non-hodgkin's lymphoma, Role: PI, Genentech, Inc., (01/2014 - 01/2015) Status: Completed
  • SWOG-S0226 - Phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first line therapy for post menopausal women with metastatic breast cancer, Role: PI, Southwest Oncology Group, (01/2014 - 01/2015) Status: Completed
  • Merrimack Pharmaceuticals - MM-121-01-101: A phase 1-2 trial of MM-121 in combination with erlotinib in three groups of patients with non-small cell lung cancer, Role: Investigator, Merrimack Pharmaceuticals, (11/2013 - 10/2014) Status: Completed
  • SWOG - E1908: A phase II randomized trial comparing standard and low dose rituximab: Initial treatment of progressive chronic lymphocytic leukemia in elderly patients using alemtuzumab and rituximab, Role: PI, Southwest Oncology Group, (07/2013 - 07/2014) Status: Completed
  • Novartis - CSOM230C2303: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs. octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues, Role: Investigator, Novartis Pharmaceuticals Corporation, (06/2013 - 06/2014) Status: Completed
  • Celgene - protocol CC-5013-MCL-001: A phase II multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent, lenalidomide (Revlimid®) in patients with mantle cell non-Hodgkin's lymphoma who have relapsed or progressed after treatment with bortezomib or are refractory to bortezomib (protocol CC-5013-MCL-001). The "emerge" trial., Role: PI, Celgene, Inc., (04/2013 - 04/2014) Status: Completed
  • SWOG - S0941: Phase II study of sorafenib (NSC-724772) and erlotinib (NSC-718781) in patients with advanced gallbladder carcinoma or cholangiocarcinoma, Role: Investigator, Southwest Oncology Group, (03/2013 - 03/2014) Status: Completed
  • BiPar Sciences Inc. - 20090321: Randomized phase 3 trial of gemcitabine/carboplatin with or without BSI-201 (SAR240550) (a PARP1 inhibitor) in subjects with previously untreated stage IV squamous non-small-cell lung cancer (NSCLC), Role: Investigator, BiPar Sciences, Inc., (02/2013 - 02/2014) Status: Completed
  • Wyeth research division of Wyeth Pharmaceuticals Inc. - 3129K7-2001-WW: A phase II study of inotuzumab ozogamicin (CMC-544) in subjects with indolent non-Hodgkin's lymphoma (NHL) that is refractory to or has relapsed after rituximab and chemotherapy or radioimmunotherapy, Role: PI, Wyeth Pharmaceuticals, Inc., (02/2013 - 02/2014) Status: Completed
  • SWOG 93-13. Phase III Comparison of Adjuvant Chemotherapy with High-dose Cyclophosphamide Plus Doxorubicin (AC)Versus Sequential Doxorubicin Followed by Cyclophosphamide (A-->C) in High-risk Breast Cancer Patients with 0-3 Positive Nodes (Intergroup), Role: PI, Southwest Oncology Group, (02/2013 - 02/2014) Status: Completed
  • SWOG-E2197. Phase III study of adriamycin/taxotere vs adriamycin/cytoxan for the adjuvant treatment of node positive of high risk node negative breast cancer, Role: PI, Southwest Oncology Group, (02/2013 - 01/2014) Status: Completed
  • SWOG 9701. Phase III randomized trial of 12 months vs. 3 months of paclitaxel in patients with advanced ovarian cancer, fallopian tube or primary peritoneal cancer who attain a clinically defined complete response following platinum/paclitaxel-based chemotherapy, Role: PI, Southwest Oncology Group, (12/2012 - 12/2013) Status: Completed
  • Bristol-Myers Squibb - CA 184-043: A randomized, double-blind, phase III trial comparing Ipilimumab vs placebo following radiotherapy in subjects with Castration Resistant Prostate Cancer (CRPC) that have received prior treatment with Docetaxel, Role: PI, Bristol-Myers Squibb Company, (12/2012 - 12/2013) Status: Completed
  • Novartis - Protocol CRAD001J2101: A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer, Role: Investigator, Novartis Pharmaceuticals Corporation, (11/2012 - 11/2013) Status: Completed
  • Novartis - CZOL446EUS147: A multicenter, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid and circulating tumor cell measurements in patients with HER2-negative metastatic breast cancer without bone metastasis, Role: Investigator, Novartis Pharmaceuticals Corporation, (08/2012 - 08/2013) Status: Completed
  • BMS - CA182-034: A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to sorafenib: the BRISK PS study, Role: Investigator, Bristol-Myers Squibb Company, (10/2011 - 10/2012) Status: Completed
  • SWOG 9410. Doxorubicin Dose Escalation, With or Without Taxol, as Part of the CA Adjuvant Chemotherapy Regimen for Node Positive Breast Cancer: A Phase III Intergroup Study, Role: PI, Southwest Oncology Group, (08/2011 - 08/2012) Status: Completed
  • Oncotherapeutics - C10953/6270: A phase III study of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma, Role: PI, Oncotherapeutics, (08/2011 - 08/2012) Status: Completed
  • AMGEN-20060464: A phase 1b/2 study of AMG 655 in combination with modified FOLFOX6 and bevacozimab for the first line treatment of subjects with metastatic colorectal cancer, Role: Investigator, Amgen, Inc., (07/2011 - 07/2012) Status: Completed
  • NewLink Genetics Corporation - NLG-0405: A phase III study of chemotherapy and chemoradiotherapy with or without HyperAcute - pancreatic (Algenpantucel-L) immunotherapy in subjects with surgically resected pancreatic cancer, Role: Investigator, NewLink Genetics Corporation, (07/2011 - 07/2012) Status: Completed
  • GlaxoSmithKline (GSK)-LPT109747 - An exploratory, phase II trial to determine the association of lapatinib induced fluoropyrimidine gene changes with efficacy parameters of lapatinib and capecitabine in first line gastric cancer, Role: Investigator, GlaxoSmithKline, (05/2011 - 05/2012) Status: Completed
  • Genmab-GEN205 - An open label single arm trial investigating zalutumumab, a human monoclonal anti-EGF receptor antibody, in combination with palliative care in patients with non-curable squamous cell carcinoma of the head and neck who have failed standard platinum-based chemotherapy, Role: Investigator, GENMAB, (05/2011 - 05/2012) Status: Completed
  • CTI-PIX203 Cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R) and cyclophosphamide, pixantrone, vincristine, prednisone plus rituximab (CPOP-R) in elderly patients with diffuse large-B-cell lymphoma a phase II randomized, multicenter, comparative trial., Role: PI, Cell Therapeutics, Inc., (04/2011 - 04/2012) Status: Completed
  • Oncotherapeutics - DVD-R-2009: A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide (DVD-R) for patients with relapsed/refractory multiple myeloma, Role: PI, Oncotherapeutics, (04/2011 - 04/2012) Status: Completed
  • OSI-774-302: A multi-center, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors (RADIANT), Role: Investigator, OSI Pharmaceuticals, Inc., (02/2011 - 02/2012) Status: Completed
  • Abraxis Bioscience, LLC - CA033: An open label, multicenter, phase III trial of ABI-007 vs dacarbazine in previously untreated patients with metastatic malignant melanoma, Role: Investigator, Abraxis BioScience, (02/2011 - 02/2012) Status: Completed
  • Sanofi-Aventis-EFC 10261: A multi-center, randomized, double-blind study comparing aflibercept versus placebo in patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC), Role: Investigator, Sanofi-Aventis U.S., Inc., (01/2011 - 01/2012) Status: Completed
  • Oncotherapeutics - X05272/DOXILMMY2010: A phase II study of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) for patients with newly diagnosed Multiple Myeloma (MM), Role: PI, Oncotherapeutics, (10/2010 - 10/2011) Status: Completed
  • 26866138-MMY-3002 - An open-label, randomized study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated multiple myeloma, Role: PI, Johnson & Johnson, (09/2010 - 09/2011) Status: Completed
  • Millennium Pharmaceuticals, Inc. protocol C05012 - A two-arm, non-randomized, multicenter, phase 2 study of Velcade® (bortezomib) in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in subjects with relapsed follicular lymphoma, Role: PI, Millennium Pharmaceuticals, Inc., (08/2010 - 08/2011) Status: Completed
  • Aptium 05LUN01 - A phase I/II clinical trial of bortezomib (velcade) + pemetrexed (alimta) in previously treated patients with advanced non-small cell lung cancer, Role: Investigator, Aptium Oncology Research Network, (06/2010 - 06/2011) Status: Completed
  • Genentech - protocol AVF3671g: a randomized, double blind, placebo controlled, phase IIIb trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for first line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer, Role: Investigator, Genentech, Inc., (04/2010 - 03/2011) Status: Completed
  • SWOG 88-14. Phase III comparison study of adjuvant chemoendocrine therapy with CAF and concurrent or delayed Tamoxifen to Tamoxifen alone in postmenopausal patients with involved axillary lymph nodes and positive peceptors, Role: PI, Southwest Oncology Group, (03/2010 - 03/2011) Status: Completed
  • Gloucester Pharmaceuticals, Inc. - GPI-08-0006: A phase II trial of romidepsin and bortezomib for multiple myeloma patients with relapsed or refractory disease, Role: PI, Gloucester Pharmaceuticals, Inc., (02/2010 - 02/2011) Status: Completed
  • Novartis - CASA404A2301: A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non small-cell lung cancer (NSCLC), Role: Investigator, Novartis Pharmaceuticals Corporation, (01/2010 - 01/2011) Status: Completed
  • DOXIL-MMY-3001-A randomized controlled study of DOXIL/CAELYX (doxorubicin HCl liposome injection) and VELCADE (bortezomib) or VELCADE monotherapy for the treatment of relapsed multiple myeloma, Role: PI, Johnson & Johnson, (10/2009 - 10/2010) Status: Completed
  • Dendreon Corporation, Protocol D9902B: A randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen presenting cells loaded with PA2024 (Provenge®, APC8015) in men with metastatic androgen independent prostatic adenocarcenoma, Role: Investigator, Dendreon Corporation, (09/2009 - 09/2010) Status: Completed
  • SWOG 9304. Postoperative evaluation of 5-FU by bolus injection versus 5-FU by prolonged venous infusion prior to and following combined prolonged venous infusion plus pelvic XRT versus bolus 5-FU plus leucovorin plus levamisole prior to and following combined pelvic XRT plus bolus 5-FU plus leucovorin in patients with rectal cancer, phase II intergroup., Role: PI, Southwest Oncology Group, (08/2009 - 08/2010) Status: Completed
  • SWOG-JMA17: A phase III randomized double blind study of letrozole vs placebo in women with primary breast cancer completing five or more years of adjuvant tamoxifen, Role: PI, Southwest Oncology Group, (08/2009 - 08/2010) Status: Completed
  • Wyeth - 3129K4-3301-WW - An open-label, randomized, phase 3 study of inotuzumab ozogamicin (CMC- 544) administered in combination with rituximab compared to a defined investigator's choice therapy in subjects with relapsed or refractory, CD22-positive, follicular b-cell Non-Hodgkin's lymphoma, Role: PI, Wyeth Pharmaceuticals, Inc., (10/2008 - 10/2009) Status: Completed
  • Alexion explore P06-001: Examination of PNH by level of CD59 on red and white blood cells in bone marrow failure syndromes, Role: PI, Alexion Pharmaceuticals, (09/2008 - 09/2009) Status: Completed
  • Cell Genesys, Inc-G-0034 - A phase 3 randomized, open-label study of docetaxel in combination with CG1940 and CG8711 versus docetaxel and prednisone in taxane-naïve patients with metastatic hormone-refractory prostate cancer with pain., Role: PI, Cell Genesys, Inc., (08/2008 - 08/2009) Status: Completed
  • SWOG-S0622 - Phase II studies of two different schedules of dasatinib (NSC-732517) in bone-metastasis predominant metastatic breast cancer, Role: Investigator, Southwest Oncology Group, (06/2008 - 06/2009) Status: Completed
  • AT-101-CS-101 An open-label, multicenter, phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy, Role: Investigator, Ascenta Therapeutics Inc., (01/2008 - 01/2009) Status: Completed
  • AMGEN - 20020715 - Chemotherapy administered every 2 weeks with or without a single injection of pegfilgrastim as first or second line treatment in subjects with locally advanced or metastatic colon cancer, Role: PI, Amgen, Inc., (10/2007 - 10/2008) Status: Completed
  • AMGEN - Protocol 20030250 - A phase 2 multicenter single arm clinical trial of ABX-EGF monotherapy in subjects with metastatic colorectal cancer whose tumors express low or negative EGFR levels by immunohistochemistry following treatment with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy, Role: PI, Immunex/Abgenix, (03/2007 - 03/2008) Status: Completed
  • Amgen (ABX-EGF) 20030167 - A phase 2 multicenter single arm clinical trial of ABX-EGF monotherapy in subjects with metastatic colorectal cancer following treatment with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy, Role: PI, Immunex/Abgenix, (08/2006 - 08/2007) Status: Completed
  • IMMUNEX 54.0009 - a clinical trial of the safety and efficacy of ABX - EGF in combination with Irinotecan, Leucovorin, and 5-Fluorouacil in patients with metastatic colorectal cancer, Role: Investigator, Immunex/Abgenix, (01/2006 - 01/2007) Status: Completed
  • Immunex 54.0005 - an open label phase 2 clinical trial to evaluate the safety and efficacy of abx-egf in patients with metastatic colorectal carcinoma., Role: Investigator, Immunex/Abgenix, (01/2006 - 01/2007) Status: Completed
  • A pilot study of escalating doses of Thalidomide combined with COX-2 inhibitor (Celecoxib) for treatment of unresectable recurrent soft tissue sarcoma, Role: Investigator, Celgene, Inc., (08/2005 - 08/2006) Status: Completed
  • IDEC 106-1001 - Phase II trial of Zevalin (Ibritumomab Tiuxetan) followed by Rituxan (Rituximab) maintenance in previously treated low grade non-Hodgkin's Lymphoma, Role: Investigator, IDEC Pharmaceuticals Corporation, (06/2005 - 06/2006) Status: Completed
  • A randomized phase II trial of two chemotherapy combination regimens (Docetaxel/Irinotecan or Gemcitabine/Irinotecan with or without Celecoxib) in patients with advanced non-small cell lung cancer that has failed one prior regimen of anti-cancer treatment CPTAIV-0020-362., Role: Investigator, Pharmacia, (12/2004 - 12/2005) Status: Completed
  • S9916 Docetaxel and estramustine versus mitoxantrone and prednisone for advanced, hormone refractory prostate cancer, Phase III, Role: Investigator, Southwest Oncology Group, (08/2004 - 08/2005) Status: Completed
  • Roche-ML 16323 A phase II study of oral Xeloda in combination with intravenous irinotecan in patients with locally advanced and/or metastatic colorectal cancer, Role: Investigator, Roche Laboratories Inc., (08/2004 - 08/2005) Status: Completed
  • Millenium M34101-040-an international, non-comparative, open-label study of PS-341 administered to patients with multiple Myeloma who experienced relapsed or progressive disease after receiving at least four previous treatment regimens or experienced progressive disease after Dexamethasone in Millennium Protocol M34101-039a, Role: Investigator, Millennium Pharmaceuticals, Inc., (07/2004 - 07/2005) Status: Completed
  • Super-Gen-D-0007 A randomized, open label, phase III trial of decitabine versus supportive care in adults with advanced-stage of myelodysplastic syndrome [Protocol Version dated 10/26/01; Amendment #3], Role: Investigator, SUPERGEN, (02/2004 - 02/2005) Status: Completed
  • AMGEN Protocol Number 20020122 - a randomized, open label, multicenter study of primary prophylaxis with Neulasta (pegfilgrastim) versus secondary prophylaxis as an adjunct to chemotherapy in elderly subjects (>65 y.o.) with cancer, Role: Investigator, Amgen, Inc., (01/2004 - 01/2005) Status: Completed
  • A phase II study of Nipent (pentostatin) in low grade malignancy non-Hodgkin's lymphomas, Role: Investigator, SUPERGEN, (11/2003 - 11/2004) Status: Completed
  • An international, multi-center, randomized, open-label study of PS-341 versus high-dose Dexamethasone in patients with relapsed or refractory multiple myeloma, Millennium Pharmaceuticals, Inc., (06/2002 - 06/2003) Status: Closed
  • Phase III randomized study of RFS 2000 (9-Nitro camptothecin, RFS 2000) versus gemcitabine HCl in chemonaive pancreatic cancer patients, Role: Investigator, SUPERGEN, (08/2001 - 08/2002) Status: Completed
  • A phase II, open label, prospective, randomized, controlled, multicenter study of navelbine in combination with gemzar versus paraplatin in combination with taxol in chemotherapy naive subjects with inoperable, stage IIIb or IV non-small cell lung cancer: a quality of life study, Role: PI, Glaxo Wellcome Foundation, (05/2001 - 05/2002) Status: Completed
  • A pilot study of celecoxib combined with escalating doses of thalidomide for treatment of unresectable hepatocellular carcinoma (HCC), Role: PI, Celgene, Inc., (01/2001 - 01/2002) Status: Completed
  • Phase III randomized study of RFS 2000 (9-Nitro-camptothecin, 9-NC) versus 5fluorouracil (5-FU) in pancreatic cancer patients that have progressive disease following gemcitabine HCl treatment, Role: Investigator, SUPERGEN, (09/2000 - 09/2001) Status: Completed
  • SWOG R9704: A phase III study of pre and post chemoradiation 5-FU vs pre and post radiation gemcitabine for postoperative adjuvant treatment of resected pancreatic adenocarcinoma, Role: Investigator, Southwest Oncology Group, (05/2000 - 05/2001) Status: Completed
  • Randomized, double-blind, placebo-controlled trial of primary prophylaxis with recombinant human thrombopoietin (rhTPO) administered to patients receiving DHAP chemotherapy for recurrent or refractory intermediate-grade or high grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), Role: PI, Pharmacia, Status: Completed
  • Duke University Medical Center - Phase 2 Treatment of adults with brain metastases with temodar, Role: PI, Schering Plough, Status: Completed
  • NOVARTIS Protocol # CZOL446EUS16 - A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of I.V. Zometa 4mg on Pain, Quality of Life and Time in Infusion Chair in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients with Cancer-Related Bone Lesions, Role: Investigator, Novartis Pharma AG, Status: Completed
  • Emergency use of Midostaurin (PKC412), Role: PI, Novartis Pharmaceuticals Corporation, Status: Completed
  • SWOG/NRG LU003: A Biomarker-Driven protocol for previously treated ALK-Positive Non-Squamous NSCLC patients: The NCI-NRG ALK protocol, Role: Investigator, Southwest Oncology Group, Status: Completed
  • LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Preciously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)” S1900F, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)”, Role: Investigator, Southwest Oncology Group, Status: Completed
  • AMGEN - 20020132 - A study to assess symptom burden in subjects with nonmyeloid malignancies receiving chemotherapy and Aranesp TM, Role: Investigator, Amgen, Inc., Status: Completed
  • SWOG-EORTC-30987 - Randomized Phase III study comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in patients with metastatic or locally advanced urothelial cancer without prior systemic therapy for advanced disease, Role: Investigator, Southwest Oncology Group, Status: Completed
  • SunRISe-2: A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy, Role: Investigator, Janssen Research & Development, LLC, (09/2024 - 09/2025) Status: Approved
  • A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PII3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor, Role: Investigator, SynDevRx, Inc., (02/2025 - 02/2026) Status: Approved

Internal

  • Investigator Initiated: A Retrospective chart review of patients treated with immune checkpoint inhibitors (ICI) to evaluate severe and fatal adverse events in the emergency department, Role: Investigator, LLU Dept. of Pharmacy Practice, (07/2021 - 10/2024) Status: Completed
  • Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Correlation Study of Serologic Anti-SARS-CoV-2 antibody to Treatment Efficacy and Outcome, Role: Investigator, LLU Basic Science, (06/2020) Status: Approved
  • Phase II trial of outpatient intravenous interleukin-2 in malignant melanoma and metastatic kidney cancer, Role: Investigator, LLU Dept. of Medicine, (02/2012 - 02/2013) Status: Completed
  • Effect of endometrial regenerative cells on secondary brain injury after ICH, Role: PD/PI, LLU School of Medicine, (01/2012 - 12/2013) Status: Closed
  • Identification and functional analysis of very small embryonic-like stem cells, Role: PD/PI, LLU School of Medicine, (01/2012 - 12/2013) Status: Closed
  • Expression of cyclooxygenase 2 (COX-2) in hepatocellular carcinoma and effects of COX-2 inhibitors and R-flurbiprofen on growth hepatoma cell lines, Role: Investigator, LLU Dept. of Medicine, (04/2001) Status: Completed
  • A pilot study to assess the effects of hemopoietic stem cell transplantation on skeletal metabolism, Role: PI, LLU Dept. of Medicine, Status: Completed
  • Astra-Zeneca ZD 1839 An expanded access clinical program with ZD 1839 (IRESSA) for patients with advanced non-small cell lung cancer (NSCLC), Role: PI, LLU Dept. of Medicine, Status: Completed
  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved

Non-Profit Organization

  • NSABP Protocol B-42: a clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients competing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (06/2024 - 06/2025) Status: Approved
  • NSABP B52: A randomized phase III trial evaluating pathologic complete response rates in patients with hormone receptor-positive, HER2-positive, large operable and locally advanced breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without estrogen deprivation, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (06/2024 - 06/2025) Status: Approved
  • NSABP B43: A phase III clinical trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER2-positive ductal carcinoma in situ resected by lumpectomy, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (12/2024 - 12/2025) Status: Approved
  • NSABP B51 / RTOG 1304: a randomized phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (09/2024 - 09/2025) Status: Approved
  • NSABP-B31 - A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol (AC-T) to that of adriamycin and cyclophosphmide followed by taxol plus herceptin (AC-T+HC) in node-positive breast cancer patients who have tumors that overexpress HER2., Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (12/2019 - 12/2020) Status: Completed
  • NSABP B-58: A randomized open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, human epidermal receptor 2 negative breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (10/2019 - 10/2020) Status: Completed
  • National surgical adjuvant breast and bowel project (NSABP) protocol #B-40: A randomized phase III trial of neoadjuvant therapy in patients with palpable and operable breast cancer evaluating the effect on pathologic complete response (pCR) of adding capecitabine or gemcitabine to docetaxel when administered before, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (05/2018 - 05/2019) Status: Completed
  • NSABP - FB-7: A phase II randomized clinical trial evaluating neoadjuvant therapy regimens with weekly paclitaxel plus neratinib or trastuzumab or neratinib and trastuzumab followed by doxorubicin and cyclophosphamide with postoperative trastuzumab in women with locally advanced HER2-positive breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (07/2017 - 07/2018) Status: Completed
  • Gene transduced mesenchymal progenitor cell for Vitamin D delivery in acute myeloid leukemia, Role: Sponsor, American Society of Clinical Oncology, (07/2017 - 06/2018) Status: Closed
  • NSABP-B-38 - A Phase III, adjuvant trial comparing three chemotherapy regiments in women with node-positive breast cancer: docetaxel/doxorubicin/cyclophosphamide (TAC); dose-dense (DD) doxorubicin/cyclophosphamide followed by DD paclitaxel (DD AC P); DD AC followed by DD paclitaxel plus gemcitabine (DD AC PG), Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2015 - 11/2016) Status: Completed
  • NSABP-B-36 - A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (08/2015 - 08/2016) Status: Completed
  • National Surgical adjuvant breast and bowel project (NSABP) R-04 a clinical trial comparing preoperative radiation therapy and capecitabine with or with out oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (05/2014 - 05/2015) Status: Completed
  • NSABP - B32 - A randomized, phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (09/2013 - 09/2014) Status: Completed
  • NSABP P-2 - Study of tamoxifen and raloxifene (STAR) for the prevention of breast cancer, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (06/2012 - 06/2013) Status: Completed
  • NSABP-C-07 - A clinical trial comparing 5-fluorouracil (5-FU) plus leucovorin (LV) and oxaliplatin with 5-FU plus LV for the treatment of patients with stages II and III carcionoma of the colon., Role: PI, National Surgical Adjuvant Breast & Bowel Project, (05/2012 - 05/2013) Status: Completed
  • NSABP-B30. A three-armed randomized trial to compare adjuvant adriamycin and cyclophosphamide followed by toxotere (AC-T); adriamycin and toxotere (AT); and adriamycin, taxotere, and cyclophosphamide (ATC) in breast cancer patients with positive axillary lymph nodes, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (03/2012 - 03/2013) Status: Completed
  • BMS-CA-180035 A randomized two-arm multi-center, open-label phase III study of BMS-354825 administered orally at a dose of 70 mg twice daily or 140 mg once daily in subjects with chronic myelogenous leukemia in accelerated phase, in myeloid or lymphoid blast phase or with philadelphia chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec), Role: PI, Bristol-Myers Squibb Foundation, Inc., (12/2010 - 12/2011) Status: Completed
  • Protocol BMS-CA180-034 - A randomized two-by-two, multicenter, open-label phase II study of BMS-354825 administered orally at a dose of 50mg or 70mg twice daily or 100mg or 140mg once daily in subjects with chronic phase philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia who are resistant or intolerant to imatinib mesylate (Gleevec), Role: PI, Bristol-Myers Squibb Foundation, Inc., (12/2010 - 12/2011) Status: Completed
  • Protocol BMS-CA 180-188 - Dasatinib in chronic myelogenous leukemia or Philadelphia chromosome positive acute lymphoblastic subjects who are experiencing clinical benefit on current START protocols: Long term safety and efficacy, Role: PI, Bristol-Myers Squibb Foundation, Inc., (11/2010 - 11/2011) Status: Completed
  • NSABP B-27: A randomized trial comparing preoperative doxorubicin cyclophosphamide to preoperative AC followed by preoperative docetaxel and to preoperative AC followed by postoperative docetaxel in patients with operable carcinoma of the breast, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (03/2010 - 03/2011) Status: Completed
  • NSABP B-28. A Randomized Trial Evaluating the Worth of Paclitaxol (Taxol) Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast Cancer Patients with Positive Axillary Nodes, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2008 - 11/2009) Status: Completed
  • NSABP PROTOCOL C-09: A phase II clinical trial comparing oxaliplatin, capecitabine and hepatic arterial infusion of floxuridine to oxaliplatin and capecitabine in patients with resected or ablated liver metastases from colorectal cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2008 - 11/2009) Status: Completed
  • BMS - Protocol CA 180013: A Phase II study to determine the activity of BMS-354825 in subjects with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia who have disease that is resistant to high dose imatinib mesylate (Gleevec®)or who are intolerant of imatinib, Role: PI, Bristol-Myers Squibb Foundation, Inc., (12/2007 - 12/2008) Status: Completed
  • Duke University Medical Center - Phase 2 treatment of adults with progressive or recurrent primary central nervous system lymphoma with temodar, Role: Investigator, Duke University Medical Center, (05/2004 - 05/2005) Status: Completed
  • RTOG-9914 A phase II trial of concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas, Role: Investigator, Radiation Therapy Oncology Group, (08/2000 - 08/2001) Status: Completed
  • A phase II study of ORZEL given as a twice-daily regimen in the treatment of patients with metastatic colorectal cancer, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (02/2000 - 02/2001) Status: Completed